This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Gabriel SE (2001) The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 27: 269–281
Lard LR, Visser H, Speyer I, Vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111: 446–451
O’Dell JR (2004) Therapeutic strategies for rheumatoid arthritis. New Eng J Med 350: 2591–2602
Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. New Eng J Med 350: 2167–2179
Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31: 1041–1045
Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. New Eng J Med 344: 907–916
Sharp JT, Young DY, Bluhm DY, Brook A, Brower AC, Corbett M, Decker JL, Genant HK, Gofton JP, Goodman N et al (1985) How many joints in the hands and wrists should be included in a score of radiologic progression in early rheumatoid arthritis clinical trials? Arthritis Rheum 28: 1326–1335
Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 9: 789–793
Van De Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, Van Riel PLCM, Schattenkirchner M, Emery P, Burmester GR, Zeidler H et al (2003) Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12-week phase II study. Ann Rheum Dis 1168–1177
Arnett FC, Edworthy SM, Bloch DA (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324
Van De Putte LBA, Atkins C, Malaise M, Sany J, Russel AS, Van Riel PLCM, Settas L, Bijlsma JW, Todesco S, Dougados M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63: 508–516
Kremer JM (1997) Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 40: 984–985
Kremer JM (2001) Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Meed 138: 695–706
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Bibara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate The ARMADA trial. Arthritis Rheum 48: 35–45
Keystone EC, Kavanaugh AF, Sharp JT (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 50: 1400–1411
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Fischer, H.D. (2006). Adalimumab in rheumatology. In: Weinberg, J.M., Buchholz, R. (eds) TNF-alpha Inhibitors. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7438-1_8
Download citation
DOI: https://doi.org/10.1007/3-7643-7438-1_8
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7248-4
Online ISBN: 978-3-7643-7438-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)